ALS is a progressive neurodegenerative disease in which motor neurons deteriorate, weakening the muscles responsible for movement, speech, swallowing and breathing. A subset of inherited and sporadic ALS cases is associated with abnormalities in FUS, a protein normally involved in regulating RNA inside the cell nucleus. FUS can relocate to the cytoplasm, where it may become concentrated in abnormal assemblies or aggregates. These structures can disrupt RNA processing, transport and translation, while also placing stress on the cell’s systems for maintaining protein quality. Because motor neurons are exceptionally long-lived and possess axons that may extend considerable distances to reach muscle, even modest failures in protein management can have serious consequences.

The new study examines this process at the NMJ, a site increasingly recognized as an early target in ALS biology. The NMJ is not simply a passive endpoint for a motor neuron’s axon. It is a dynamic structure requiring precise coordination between the presynaptic nerve terminal, the muscle membrane and supporting molecular machinery. Motor neurons must deliver neurotransmitter to activate muscle contraction, while muscle fibers send signals that help maintain the nerve terminal. In neurodegenerative disease, this communication can weaken before the motor neuron disappears entirely. Early NMJ dysfunction may therefore represent a window in which damaged cellular processes remain reversible or at least modifiable.

Autophagy is one of the cell’s principal quality-control pathways. Through this process, cellular components are enclosed within membrane-bound structures called autophagosomes and delivered to lysosomes, organelles containing enzymes that break down and recycle their contents. Autophagy can remove damaged organelles, misfolded proteins and other material that could otherwise accumulate and interfere with normal cell function. In neurons, which cannot readily dilute toxic substances through cell division, autophagy is particularly important. However, autophagy is not a single switch that simply turns on or off. Its protective effect depends on the entire pathway functioning effectively, from cargo recognition and autophagosome formation to lysosomal degradation and recycling.

Malik, Jones, Ma and their colleagues report that inducing autophagy in their FUS-ALS model mitigated the accumulation of FUS aggregates. The observation is important because it connects a broad cellular housekeeping mechanism with a disease-linked protein directly implicated in ALS. Rather than treating FUS aggregation as an isolated structural abnormality, the findings support the view that the cell’s capacity to identify and clear problematic protein assemblies may influence the earliest functional effects of the disease. Reducing aggregate formation could preserve the intracellular environment required for normal axonal transport, synaptic maintenance and communication between motor neurons and muscle.

The reported benefits were also observed at the level of the NMJ, where autophagy induction mitigated early synaptic dysfunction. In practical terms, this suggests that improving protein clearance may help protect the nerve–muscle connection before the disease produces more extensive structural damage. Synaptic dysfunction can involve impaired neurotransmitter release, altered organization of the postsynaptic muscle membrane or instability of the contact itself. The study’s focus on these early changes is significant because a treatment that acts only after motor neurons have been lost would face a much narrower opportunity to preserve movement. By contrast, stabilizing the NMJ could potentially maintain functional communication for longer, even if the underlying disease process has not been completely eliminated.

The findings also highlight why timing may be decisive in future ALS therapies. Protein aggregates and cellular stress can create a self-reinforcing cycle: abnormal proteins interfere with normal processes, impaired quality control allows more abnormal proteins to accumulate, and the resulting stress further weakens the cell’s ability to recover. Autophagy induction could interrupt part of that cycle, but the approach is not automatically risk-free. Excessive or poorly controlled autophagy can consume essential cellular components, and stimulation of the pathway may have different effects depending on disease stage, cell type and the condition of the lysosomal system. A useful treatment would therefore need to enhance productive autophagic flux—the completion of degradation and recycling—rather than merely increase the number of autophagosomes.

Because the work was conducted in a FUS-ALS model, it should not be interpreted as evidence that an autophagy-activating drug can currently prevent or reverse ALS in people. Models are essential for isolating mechanisms, but they cannot reproduce every feature of human disease, including its genetic diversity, variable progression and complex interactions among neurons, muscle, glial cells and the immune system. The next scientific steps will include determining which molecular components of autophagy are responsible for the protective effect, establishing how long the benefit lasts and testing whether the intervention preserves motor performance and survival. Researchers will also need to assess whether similar strategies work in other ALS-associated proteinopathies, since not all forms of ALS are driven by FUS.

Nevertheless, the study provides a timely shift in perspective: the earliest battle in FUS-linked ALS may occur at the synapse, before catastrophic neuronal loss becomes visible, and the outcome may depend partly on how efficiently cells dispose of defective protein material. By linking autophagy induction with reduced FUS aggregation and improved NMJ function, the research identifies a mechanistic route that could guide future therapeutic development. The result is not yet a treatment, but it strengthens the case for targeting cellular quality control as an early strategy in neurodegenerative disease. In ALS research, where restoring lost motor neurons remains beyond current medicine, protecting the connections that remain could prove to be one of the most important opportunities for slowing decline.

Subject of Research: Autophagy induction, FUS protein aggregation, neuromuscular junction dysfunction and amyotrophic lateral sclerosis.

Article Title: Autophagy induction mitigates FUS aggregate formation and early synaptic dysfunction at the NMJ in a FUS-ALS model.

Article References: Malik, T., Jones, S., Ma, O. et al. “Autophagy induction mitigates FUS aggregate formation and early synaptic dysfunction at the NMJ in a FUS-ALS model.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03286-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03286-6

Keywords: Amyotrophic lateral sclerosis, ALS, FUS, protein aggregates, autophagy, neuromuscular junction, motor neurons, synaptic dysfunction, neurodegeneration, protein quality control

ALS, characterized by progressive motor neuron degeneration leading to muscle paralysis and eventual respiratory failure, has long been a challenge for researchers seeking to unravel its precise cellular and molecular mechanisms. Although the loss of motor neurons has been clearly established as the core pathological hallmark, the early events that precede overt neuronal death remain elusive. This study shifts the focus to the neuromuscular junction—the specialized synapse connecting motor neurons to muscle fibers—where the initial disruptions in communication and connection appear to set the stage for subsequent neurodegeneration.

The CCL2-CCR2 axis, traditionally recognized for its role in immune cell recruitment and inflammatory responses, emerges here as a central player in neuromuscular pathology. The researchers demonstrated that CCL2, a chemokine ligand, and its receptor CCR2 are aberrantly upregulated in motor neurons and surrounding glial cells in ALS models. This overexpression correlates with pronounced neuromuscular denervation, a process wherein motor nerve terminals withdraw from muscle fibers, leading to functional synapse loss.

Utilizing advanced mouse models genetically engineered to mimic human ALS, the team meticulously mapped the spatial and temporal dynamics of CCL2-CCR2 expression across disease progression. Early pre-symptomatic stages revealed subtle increases in CCL2 secretion, which were amplified as symptoms manifested. Importantly, pharmacological blockade of CCR2 signaling notably attenuated neuromuscular denervation and preserved muscle function, suggesting that this pathway’s activity is not merely correlative but causal in disease development.

A crucial innovation in this work was the deployment of high-resolution imaging techniques to observe neuromuscular junction architecture in vivo. By employing fluorescence microscopy combined with sophisticated neuronal tracing methods, the investigators documented the stepwise disassembly of nerve terminals concurrent with CCL2-CCR2 activation. These visuals not only confirmed biochemical findings but also provided compelling evidence for synaptic vulnerability as an early disease event.

The study further elucidated downstream mechanisms triggered by CCL2-CCR2 signaling. Activation of this axis instigated a cascade involving inflammatory mediators and microglial recruitment, establishing a neuroinflammatory milieu within the spinal cord microenvironment. This inflammation exacerbates synaptic stripping, reinforcing a vicious cycle that accelerates motor neuron degeneration. By dissecting this interplay between chemokine signaling and neuroimmune crosstalk, the research offers a holistic view of ALS pathology beyond mere neuronal demise.

Moreover, transcriptomic analyses of affected motor neurons revealed that CCL2-CCR2 activation disrupts cytoskeletal integrity and synaptic vesicle trafficking. These intracellular perturbations compromise axonal transport, a process essential for maintaining neuromuscular junction stability and nutrient exchange between nerve and muscle. The work ties molecular deficits directly to functional synapse failure, bridging the gap between cellular dysfunction and clinical symptoms.

Importantly, the team demonstrated that the modulation of CCL2-CCR2 is therapeutically feasible. Using monoclonal antibodies targeting CCR2, treatment delayed disease onset and improved survival rates in ALS model mice. This highlights the translational potential of these findings, positioning CCR2 antagonists as promising candidates for clinical trials aimed at halting or reversing early synaptic damage in ALS patients.

Complementing the in vivo studies, in vitro experiments with cultured motor neurons exposed to exogenous CCL2 confirmed the chemokine’s deleterious effects on neuronal health and synapse maintenance. These experiments also showed that blocking CCR2 restored motor neuron viability, directly linking receptor activity with cellular integrity. The dual approach of in vivo and in vitro validation strengthens the evidence base and assures the robustness of the conclusions.

This discovery also reframes how neuroinflammation is viewed in ALS. While inflammatory responses have been implicated previously, the identification of a specific chemokine axis driving synaptic degeneration underscores a targeted mechanism rather than a broad unspecific immune activation. This specificity opens possibilities for precision medicine approaches where targeted blockade of chemokine receptors could mitigate neurodegeneration without compromising systemic immune functions.

The impact of this research transcends ALS alone. Since the CCL2-CCR2 axis is implicated in various neurodegenerative and inflammatory conditions, these insights could influence therapeutic strategies in diseases where synapse loss is a hallmark, such as multiple sclerosis and certain forms of peripheral neuropathy. Elucidating common molecular drivers of synaptic pathology could pave the way for unified treatment paradigms across neurological disorders.

Beyond molecular science, this study advances our understanding of synaptic homeostasis and neuron-glia interactions in health and disease. It highlights the delicate balance maintained at the neuromuscular junction and the devastating consequences when chemokine signaling is dysregulated. This knowledge enriches the broader neurobiology field, informing future research into synaptic resilience and repair mechanisms.

The publication also offers hope to the ALS community, which has long awaited breakthroughs that can alter the grim prognosis associated with this disease. By identifying a modifiable molecular target acting at early disease stages, the findings suggest potential diagnostic markers and therapeutic windows previously unrecognized. Early intervention in ALS, guided by biomarkers of CCL2-CCR2 activity, could revolutionize patient care.

Nógrádi and colleagues emphasize that while the blockade of CCR2 signaling offers promise, comprehensive clinical studies will be required to translate these preclinical successes into humans. Differences in immune system complexity, chemokine dynamics, and disease heterogeneity pose challenges that future research must address. Nonetheless, this work lays a solid foundation for such endeavors.

In conclusion, the elucidation of the CCL2-CCR2 chemokine axis as a driver of neuromuscular denervation in ALS represents a major leap forward in both basic neurobiology and clinical neurodegeneration research. This meticulously executed study blends genetic, pharmacological, imaging, and transcriptomic approaches to unravel a mechanistic pathway with profound implications. Its findings set the stage for new therapeutic interventions aimed at preserving neuromuscular connectivity, ultimately aspiring to halt or even reverse the progression of ALS.

As neuroscience continues to unravel the complexities of neurodegenerative diseases, the identification of targeted molecular drivers such as the CCL2-CCR2 axis offers a beacon of hope. The prospect of modulating inflammation-induced synaptic loss transforms ALS from an inexorable, untreatable illness into a condition where early and precise intervention could alter the trajectory of suffering. This work stands as a testament to the power of integrative biomedical research in tackling humanity’s most challenging diseases.

Subject of Research: Neurodegeneration; Amyotrophic Lateral Sclerosis; Neuromuscular Junction Pathology; Chemokine Signaling

Article Title: The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis

Article References:
Nógrádi, B., Molnár, K., Kristóf, R. et al. The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis. Nat Commun 16, 7053 (2025). https://doi.org/10.1038/s41467-025-62351-3

Image Credits: AI Generated